Deferred registration - AstraZeneca/United Kingdom Code: D7260C00014

AstraZeneca/United Kingdom Code: D7260C00014 [Full scientific title to be added on or before the deferral expiry date]

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN99796543

Enrollment

100

Registered

2026-09-11

Start date

2027-05-03

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. Other

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Eligibility

Sex/Gender

All

Age

0 Years to 1 Years

Inclusion criteria

Inclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Exclusion criteria

Exclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Design outcomes

Primary

Measure	Time frame
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]	—

Countries

England, United Kingdom

Contacts

Public ContactMarleen Roels

marleen.roels@astrazeneca.com+46720140219

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Sep 19, 2026